-
Document de presse | 2021.06.24
Dengue: discovery of a new indicator for predicting disease severity
Dengue virus causes an average of 500,000 hemorrhagic cases annually, posing a threat to over 2.5 billion people throughout the world every year. Scientists at the Institut Pasteur du Cambodge and the Rockefeller University working in collaboration with the Institut Pasteur (CNRS joint laboratory) have revealed that the absence of a sugar known as fucose forming the structure of anti-dengue...
-
News | 2021.07.09
The Institut Pasteur International Network is evolving and becoming the Pasteur Network
A new system of governance is being introduced for the Institut Pasteur International Network and its 33 members, which since 2011 have been part of the Pasteur International Network association, which was chaired by the Institut Pasteur President Stewart Cole. Ten years on, the Network is adopting a more participatory, balanced mode of governance and a more structured business model. The...
-
News | 2021.07.15
BCG vaccine: the first tuberculosis vaccination took place a century ago
July 2021 marks the hundredth anniversary of the first vaccination of an infant with the BCG vaccine. Although tuberculosis is still one of the ten leading causes of mortality worldwide, this vaccine, developed at the Institut Pasteur, led to a steep reduction in the number of cases. We take a look back at how the vaccine was discovered.Albert Calmette arrived in Lille in 1897 as director of the...
-
News | 2021.07.19
COVID-19: interaction identified between SARS-CoV-2 and unusual RNA structures in human cells
Replication of SARS-CoV-2, the virus responsible for COVID-19, depends on a series of interactions between viral proteins and different cellular partners such as nucleic acids (DNA or RNA). Characterizing these interactions is crucial to elucidate the process of viral replication and identify new drugs for treating COVID-19.An interdisciplinary consortium of scientists from the Institut Pasteur,...
-
News | 2021.07.19
AFROSCREEN, boosting variant surveillance in 13 African countries
The Agence française de développement (AFD) and ANRS | Maladies infectieuses émergentes, in partnership with the Institut Pasteur, IRD, and laboratories across 13 African countries, are launching the joint AFROSCREEN project. This project meets an urgent need for surveillance of the development of SARS-CoV-2 variants and other emerging pathogens by bolstering laboratory genomic sequencing...
-
Document de presse | 2021.07.16
ComCor study: analysis of the effectiveness of messenger RNA vaccines against the SARS-CoV-2 Alpha and Beta variants in France
Over the past six months, the World Health Organization has categorized four SARS-CoV-2 variants as being "of concern" because they are more transmissible or may escape the immune response. They have been termed the Alpha, Beta, Gamma and Delta variants. Scientists from the Institut Pasteur, in collaboration with the French National Health Insurance Fund (CNAM), Ipsos and Santé publique France,...
-
News | 2021.07.27
The 2021 Pasteur Vallery-Radot Prize (awarded by the National Library of France - BnF)
The National Library of France (BnF) awarded the two Prix Pasteur Vallery-Radot 2021 to Jérôme Gros and Etienne Patin, researchers at the Institut Pasteur. Here are the presentation of the two laureates. This year, the two Pasteur Vallery-Radot Prizes went to:Jérôme Gros, Research Director at the Institut Pasteur and Head of the Dynamic Regulation of Morphogenesis Unit, for his research...
-
Document de presse | 2021.07.21
SARS-CoV-2 damages ciliated cells and inhibits mucociliary clearance in the airways
COVID-19 is a viral disease with respiratory symptoms that can induce fatal pneumonia. Understanding how SARS-CoV-2 spreads in the respiratory tract can help scientists identify the parameters controlling the severity of infection. Scientists from the Institut Pasteur, the CNRS and Inserm found that SARS-CoV-2 multiplies efficiently in the respiratory tract, and that it primarily targets ciliated...
-
Document de presse | 2021.07.12
Ivermectin alleviates Covid-19 symptoms in an animal model
Since the start of the COVID-19 pandemic, various therapeutic approaches have been explored to tackle the disease. Scientists from the Institut Pasteur have shown that ivermectin, a drug used commercially as an antiparasitic treatment, offers protection from COVID-19 symptoms in an animal model. The scientists observed that taking ivermectin was associated with reduced inflammation in the...
-
Page avancée | 2021.08.09
Committing to Open Science
The Institut Pasteur has been acting in favor of Open Science by adopting two founding texts in May 2021: a Charter for Open Access to publications and a Policy for the management and sharing of research data and software code.
